(J Cell Mol Med 2024, 2024: CML cell-line study establishing a flumatinib-resistant K562 subline that over-expresses P-glycoprotein, ABCC1 and ABCC4 and remains sensitive to ivermectin, which suppressed the resistant phenotype.
This cell line exhibited cross-resistance to imatinib and doxorubicin, but remained sensitive to the antiparasitic agent ivermectin, which possesses antitumoural effects.
(J Cell Mol Med 2024, 2024: CML cell-line study establishing a flumatinib-resistant K562 subline that over-expresses P-glycoprotein, ABCC1 and ABCC4 and remains sensitive to ivermectin, which suppressed the resistant phenotype. Study type: CML cell line K562 and derived flumatinib-resistant K562/FLM, in vitro. N: n/a. Country: China (Yuebei People's Hospital, Shantou University Medical College). Dose: not stated in the abstract. Declared COI: 'The authors confirm that there are no conflicts of interest.' Comparator: parental K562 cells and flumatinib alone. Supports the MDR-reversal claim by showing retained ivermectin sensitivity in a P-gp/ABCC-overexpressing resistant line. Study type: lab.
